Pilot Pharmacokinetic Study of Human Immunodeficiency Virus-Infected Patients Receiving Tenofovir Disoproxil Fumarate (TDF): Investigation of Systemic and Intracellular Interactions between TDF and Abacavir, Lamivudine, or Lopinavir-Ritonavir
- 1 May 2009
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (5) , 1937-1943
- https://doi.org/10.1128/aac.01064-08
Abstract
Previous work has demonstrated the existence of systemic interaction between tenofovir (TFV) disoproxil fumarate (TDF) and didanosine as well as between TDF and lopinavir-ritonavir (LPV/r). Here we investigated TDF interactions with the nucleoside reverse transcriptase inhibitors (NRTIs) lamivudine (3TC) and abacavir (ABC), comparing both the concentrations of nucleoside/nucleotide reverse transcriptase inhibitors in plasma and the intracellular concentrations of their triphosphate metabolites (NRTI-TP) for human immunodeficiency virus-infected patients receiving these NRTIs with TDF and after 4 weeks of TDF interruption. We also looked at interactions between TDF-ABC and LPV/r, comparing patients receiving or not receiving LPV/r. Blood samples were taken at baseline and at 1, 2, and 4 h after dosing. Liquid chromatography-tandem mass spectrometry was used to measure NRTIs and NRTI-TPs. Statistical analyses were performed on pharmacokinetic parameters: the area under the concentration-time curve from 0 to 4 h (AUC0-4), the maximum concentration of the drug (Cmax), and the residual concentration of the drug at the end of the dosing interval (Ctrough) for plasma and the AUC0-4andCtroughfor intracellular data. Among the groups of patient discontinuing TDF, the very long intracellular half-life of elimination (150 h) of TFV-DP (the diphosphorylated metabolite of TFV, corresponding to a triphosphorylated species) was confirmed. Comparison between groups as well as the longitudinal study showed no significant systemic or intracellular interaction between TDF and ABC or 3TC. Significant differences were observed between patients receiving LVP/r and those receiving nevirapine. For ABC, plasma exposure was decreased (40%) under LVP/r, while, in contrast, plasma exposure to TFV was increased by 50% and the intracellular TFV-DP AUC0-4was increased by 59%. A trend for a gender effect was observed for TFV-DP at the intracellular level, with higher andCtroughvalues for women.Keywords
This publication has 45 references indexed in Scilit:
- Effects of Human Immunodeficiency Virus Protease Inhibitors on the Intestinal Absorption of Tenofovir Disoproxil Fumarate In VitroAntimicrobial Agents and Chemotherapy, 2007
- Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B VirusAntimicrobial Agents and Chemotherapy, 2006
- Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV‐Infected Antiretroviral‐Naive SubjectsThe Journal of Infectious Diseases, 2005
- Treatment for Adult HIV InfectionJAMA, 2004
- Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral loadAIDS, 2004
- Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individualsAIDS, 2003
- Pancreatitis Treated with Didanosine and Tenofovir Disoproxil FumarateClinical Infectious Diseases, 2003
- Improved method for the simultaneous determination of d4T, 3TC and ddl intracellular phosphorylated anabolites in human peripheral‐blood mononuclear cells using high‐performance liquid chromatography/tandem mass spectrometryRapid Communications in Mass Spectrometry, 2002
- Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell lineJournal of Pharmaceutical Sciences, 2001
- Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteersBritish Journal of Clinical Pharmacology, 1998